• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Affimed N.V.

    < Previous 1 2 Next >
    Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed to Present at the Cantor Global Healthcare Conference 2024
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Reports Second Quarter 2024 Financial Results & Business Update
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Appoints Shawn M. Leland as Chief Executive Officer
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Reports First Quarter 2024 Financial Results & Business Update
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Annual General Meeting of Shareholders
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Reports 2023 Financial Results and Operational Progress
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces 1-for-10 Reverse Stock Split
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Leadership Change and Organizational Restructuring
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed to Participate in Upcoming Investor Conferences
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    Affimed Announces Listing Transfer to Nasdaq Capital Markets
    From Affimed N.V.
    Via GlobeNewswire
    Tickers AFMD
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.